



Novartis India Announces Improved Results for the Quarter and Half-Year ended 30 September 2010

At a meeting held in Mumbai today, the Board of Novartis India Limited approved results for the quarter and half-year ended 30 September 2010. During the quarter ended September 2010 sales of Rs 184.9 crore registered a growth of 14.5% over sales during the corresponding previous quarter.

During the quarter under review, our core business, Pharmaceuticals with sales of Rs 129.0 crore grew by 13.7% over the corresponding previous period (Rs 113.5 crore). The Generics business recorded sales of Rs 11.4 crore (Rs 10.0 crore). The Animal Health business registered sales of Rs 18.1 crore (Rs 17.4 crore). OTC business registered sales of Rs 26.5 crore (Rs 20.7 crore).

Profit before tax was Rs 59.6 crore (Rs 50.4 crore). After providing for tax of Rs 19.0 crore (Rs 17.2 crore), profit after tax stood at Rs 40.6 crore (Rs 33.3 crore).

During the half-year ended September 2010 sales of Rs 353.2 crore registered a growth of 12.2% over sales during the corresponding previous six months period.

During the half-year under review, our core business, Pharmaceuticals with sales of Rs 251.2 crore grew by 11.1% over the corresponding previous period (Rs 226.1 crore). The Generics business recorded sales of Rs 22.6 crore (Rs 20.8 crore). The Animal Health business registered sales of Rs 33.0 crore (Rs 30.2 crore). OTC business registered sales of Rs 46.4 crore (Rs 37.7 crore).

Profit before tax was Rs 107.1 crore (Rs 100.7 crore). After providing for tax of Rs 35.0 crore (Rs 35.7 crore), profit after tax stood at Rs 72.1 crore (Rs 65.0 crore).

Note: All figures in brackets refer to prior corresponding period.

Issued by Corporate Communications on 21 October 2010
For further information contact: S.Pinto/L.Vaz on Tel: 24958804/5
e-mail sverlana.pinto@novartis.com, liana.vaz@novartis.com

